BioVersys AG (XSWX:BIOV) Other Financing: CHF-6.94 Mil (TTM As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.30
View Full Analysis

What is BioVersys AG Other Financing?

BioVersys AG XSWX:BIOV -2.59% 4 Other Financing is CHF-6.94 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's Other Financing for the six months ended in Dec. 2025 was CHF-0.02 Mil.

BioVersys AG's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-6.94 Mil.

BioVersys AG Other Financing Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Other Financing Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Other Financing
-0.38 -6.94

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Other Financing -0.48 0.10 -6.92 -0.02
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-6.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of CHF-6.94 Mil mean?
BioVersys AG (XSWX:BIOV) has a Other Financing of CHF-6.94 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for BioVersys AG and its competitors.
Is BioVersys AG's Other Financing too high?
BioVersys AG's current Other Financing is CHF-6.94 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Other Financing compare to VRTX and REGN?
BioVersys AG's Other Financing of CHF-6.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for BioVersys AG and its competitors. BioVersys AG's current Other Financing is CHF-6.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Other Financing of CHF-6.94 Mil. The current Other Financing is CHF-6.94 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Other Financing is CHF-6.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30
Price